News - bapineuzumab, Janssen

Filter

Current filters:

bapineuzumabJanssen

Popular Filters

Pfizer and Janssen's bapineuzumab fails to meet one Ph III study endpoints for Alzheimer's

24-07-2012

US drugs behemoth Pfizer (NYSE: PFE) revealed yesterday that the co-primary clinical endpoints, change…

bapineuzumabJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

Back to top